U-LABA/ICS Effects on Exercise Performance, Vilanterol

Launched by MORTEN HOSTRUP, PHD · Sep 27, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring how a specific medication, a combination of vilanterol and fluticasone furoate, affects exercise performance in healthy, physically active adults. Researchers want to see if using this medication can help improve how well people perform during exercise after taking it. The trial is currently looking for participants who are between 18 and 39 years old and exercise regularly for more than five hours each week.

To join the study, participants should not have severe asthma or certain heart conditions, and they should not be taking medications that might interfere with the results of the trial. Participants can expect to take the medication and then undergo tests to measure their exercise performance. This study aims to gather important information that could help enhance treatment options for people who are physically active.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-39
• • Physically active \> 5 h weekly
• • Maximal oxygen consumption classified as high or very high
• Exclusion Criteria:
• • Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
• • ECG abnormality
• • ACQ score \> 1.5
• • Severe bronchial hyperreactivity as determined by mannitol test
• • FEV1/FVC ratio \< 0.7 determined with spirometry
• • Chronic illness determined to be a potential risk for participant during study
• • In chronic treatment with medication that may interfere with study results
• • Pregnancy
• • Smoker
• • Blood donation during the past 3 months